Global X MANAGEMENT CO LLC grew its holdings in Hologic, Inc. (NASDAQ:HOLX) by 16.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 13,944 shares of the medical equipment provider’s stock after purchasing an additional 1,982 shares during the period. Global X MANAGEMENT CO LLC’s holdings in Hologic were worth $512,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Koch Industries Inc. lifted its stake in shares of Hologic by 15,554.1% in the 2nd quarter. Koch Industries Inc. now owns 1,149,481 shares of the medical equipment provider’s stock valued at $1,125,000 after purchasing an additional 1,142,138 shares during the last quarter. Picton Mahoney Asset Management lifted its stake in Hologic by 8.1% during the 2nd quarter. Picton Mahoney Asset Management now owns 57,150 shares of the medical equipment provider’s stock worth $2,593,000 after acquiring an additional 4,300 shares in the last quarter. Russell Investments Group Ltd. lifted its stake in Hologic by 229.7% during the 2nd quarter. Russell Investments Group Ltd. now owns 1,059,586 shares of the medical equipment provider’s stock worth $48,100,000 after acquiring an additional 738,215 shares in the last quarter. Swiss National Bank lifted its stake in Hologic by 12.8% during the 2nd quarter. Swiss National Bank now owns 1,159,424 shares of the medical equipment provider’s stock worth $52,615,000 after acquiring an additional 131,300 shares in the last quarter. Finally, Rhumbline Advisers lifted its stake in Hologic by 1.4% during the 2nd quarter. Rhumbline Advisers now owns 548,465 shares of the medical equipment provider’s stock worth $24,889,000 after acquiring an additional 7,727 shares in the last quarter. 96.41% of the stock is currently owned by institutional investors and hedge funds.

Several equities analysts recently issued reports on the company. Royal Bank Of Canada reissued a “sector perform” rating and set a $45.00 target price (down previously from $50.00) on shares of Hologic in a research note on Wednesday, August 9th. BidaskClub lowered Hologic from a “hold” rating to a “sell” rating in a research note on Wednesday, August 9th. Barclays PLC reissued an “equal weight” rating and set a $51.00 target price (down previously from $53.00) on shares of Hologic in a research note on Wednesday, August 9th. Needham & Company LLC reissued a “buy” rating on shares of Hologic in a research note on Tuesday, August 1st. Finally, Piper Jaffray Companies reissued a “buy” rating and set a $48.00 target price on shares of Hologic in a research note on Thursday, November 9th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and nine have given a buy rating to the stock. Hologic has an average rating of “Buy” and an average price target of $47.54.

Shares of Hologic, Inc. (NASDAQ HOLX) opened at $39.96 on Friday. The stock has a market capitalization of $11,519.39, a PE ratio of 19.78, a P/E/G ratio of 1.93 and a beta of 0.93. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.79 and a quick ratio of 0.61. Hologic, Inc. has a 1 year low of $35.76 and a 1 year high of $46.80.

Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, November 8th. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.49 by $0.01. The firm had revenue of $802.90 million during the quarter, compared to analysts’ expectations of $792.54 million. Hologic had a return on equity of 21.69% and a net margin of 24.70%. The business’s revenue was up 10.5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.52 EPS. research analysts anticipate that Hologic, Inc. will post 2.12 earnings per share for the current year.

In other Hologic news, Director Lawrence M. Levy sold 9,596 shares of the stock in a transaction that occurred on Tuesday, October 10th. The stock was sold at an average price of $36.81, for a total transaction of $353,228.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Lawrence M. Levy sold 7,139 shares of the stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $39.04, for a total value of $278,706.56. The disclosure for this sale can be found here. Over the last three months, insiders sold 34,949 shares of company stock valued at $1,345,220. Insiders own 0.79% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of US & international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2017/11/19/hologic-inc-holx-stake-boosted-by-global-x-management-co-llc.html.

Hologic Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.